ECTRIMS – www.brainwork.md

25th September 2019

Why B-cell therapies, or why not?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-bcelltherapy.jpg 3848 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 25th September 2019 4th October 2019

The rational for B-cell therapy in multiple sclerosis (MS) was presented during ECTRIMS 2019, with David Baker (Blizard Institute, Queen Mary University of London, UK) posing the question of why…

Peter Stevenson, PhD
0
0

24th September 2019

Are stem cells in MS ready for prime time?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-stem-cells.jpg 2300 1535 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

Peter Stevenson, PhD
0
0

24th September 2019

Enough evidence for vitamin D in MS?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-vitamin-D.jpg 3450 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

The role of vitamin D in the treatment of multiple sclerosis (MS) took centre stage during the first day of ECTRIMS 2019 in Stockholm, Sweden. In a ‘Hot Topic’ session,…

Peter Stevenson, PhD
0
0

19th October 2018

Cognitive impairment in MS

https://www.brainwork.md/content/uploads/2018/10/Brainwork-MSCognitive_2048-1.jpg 2048 1153 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 19th October 2018 1st February 2019

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

Mea Holm, PhD
0
0

16th October 2018

Serum neurofilament light: A biomarker for disease activity in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustration-soluble-biomarkers-V00-03-20181012.jpg 1920 1080 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 16th October 2018 19th October 2018

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

Mea Holm, PhD
1
0

15th October 2018

Results from the MS-SMART trial unveiled

https://www.brainwork.md/content/uploads/2018/10/Brainwork-ECTRIMSSMART.jpg 3971 2975 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 15th October 2018 15th October 2018

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

Mea Holm, PhD
0
0

15th October 2018

De-risking PML: A conversation with Prof. Walter Atwood

https://www.brainwork.md/content/uploads/2018/10/Brainwork-ECTRIMS-Outside.jpg 2872 2598 Prof. Dr. Krassen Nedeltchev Prof. Dr. Krassen Nedeltchev https://secure.gravatar.com/avatar/aaadc696c1b66fe476051e7e4012d01a?s=96&d=mm&r=g 15th October 2018 23rd October 2018

We interviewed Professor Walter Atwood last week at the 2018 ECTRIMS congress in Berlin, Germany, to learn about advances in treating progressive multifocal leukoencephalopathy (PML) – an important treatment-associated infection…

Prof. Dr. Krassen Nedeltchev
0
1

12th October 2018

Fighting neurodegeneration in MS

https://www.brainwork.md/content/uploads/2018/10/Brainwork-FightingNeurodegeneration.jpg 3150 2100 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 12th October 2018 12th October 2018

The pathology of multiple sclerosis (MS) involves not only the loss of myelin sheets around the axons of neurons, but also the fragmentation of the axons themselves. At ECTRIMS 2018,…

Mea Holm, PhD
0
0

12th October 2018

MS treatment strategy: Hitting hard and early, or minimising risks through stepwise escalation?

https://www.brainwork.md/content/uploads/2018/10/Brainwork-MSTreatmentStrategy-e1540300616685.jpg 1969 1525 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 12th October 2018 12th October 2018

With more than a dozen approved treatment options for relapsing-remitting multiple sclerosis (RRMS), treatment decision making is an increasingly complex task for neurologists. At ECTRIMS 2018, the topic on which…

Mea Holm, PhD
2
0

11th October 2018

FLOODLIGHT offers illuminating outcomes for smartphone monitoring in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustrations-articles-Floodlight-V00-01-20181011-01-1.jpg 1920 1080 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 11th October 2018 11th October 2018

Smartphone-based, high-yield active and passive self-monitoring of multiple sclerosis (MS) may enhance clinical disease assessments when compared to conventional methods for detecting subtle progressive clinical changes, according to a study…

Peter Stevenson, PhD
1
0